.Nature Medicine, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medication conjugate (ADC) tisotumab vedotin caused enhanced progression-free and overall survival, triggering FDA approval as well as a brand new therapy choice for patients.